The exendin 939 concentration used in this experiment was approximately 30 times higher than its IC 50 value for CAP-induced TRPV1 activation, indicating the mode-selective characteristics of exendin 939
In this paper, we aim to elucidate the potential implications of GLP-1 agonists on sexual desire by proposing a serotonergic mechanism by which GLP-1 agonists theoretically decrease sexual desire, and a biopsychosocial perspective on why this effect may be camouflaged by competing influences
Pathophysiology of Facial Volume Loss with GLP-1 Medications The use of semaglutide and similar compounds leads to a reduction in overall body fat , including subcutaneous facial fat
Many patients begin noticing reduced hunger within the first few weeks, with visible weight changes developing progressively over several months
Each medication follows a unique dose-escalation protocol, starting with a low dose and gradually increasing over several weeks to minimise side effects whilst achieving optimal glycaemic control or weight management
The product does not appear to be available through major retailers based on the company's distribution model
